AP478A - Use of triazine compounds for the treatment of impaired memory and learning disorders. - Google Patents

Use of triazine compounds for the treatment of impaired memory and learning disorders. Download PDF

Info

Publication number
AP478A
AP478A APAP/P/1994/000627A AP9400627A AP478A AP 478 A AP478 A AP 478A AP 9400627 A AP9400627 A AP 9400627A AP 478 A AP478 A AP 478A
Authority
AP
ARIPO
Prior art keywords
impaired memory
learning disorder
pharmaceutically
treatment
dichlorophenyl
Prior art date
Application number
APAP/P/1994/000627A
Other languages
English (en)
Other versions
AP9400627A0 (en
Inventor
Martin George Baxter
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9400627A0 publication Critical patent/AP9400627A0/xx
Application granted granted Critical
Publication of AP478A publication Critical patent/AP478A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/1994/000627A 1993-03-19 1994-03-18 Use of triazine compounds for the treatment of impaired memory and learning disorders. AP478A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305693A GB9305693D0 (en) 1993-03-19 1993-03-19 Therapeutic triazine compounds and use

Publications (2)

Publication Number Publication Date
AP9400627A0 AP9400627A0 (en) 1994-04-30
AP478A true AP478A (en) 1996-03-08

Family

ID=10732358

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000627A AP478A (en) 1993-03-19 1994-03-18 Use of triazine compounds for the treatment of impaired memory and learning disorders.

Country Status (15)

Country Link
EP (1) EP0689439B1 (fr)
JP (1) JPH08507782A (fr)
AP (1) AP478A (fr)
AT (1) ATE198831T1 (fr)
AU (1) AU6217694A (fr)
DE (1) DE69426622T2 (fr)
DK (1) DK0689439T3 (fr)
ES (1) ES2153854T3 (fr)
GB (1) GB9305693D0 (fr)
GR (1) GR3035528T3 (fr)
IL (1) IL109034A (fr)
PT (1) PT689439E (fr)
TW (1) TW256773B (fr)
WO (1) WO1994021260A1 (fr)
ZA (1) ZA941938B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021121A1 (fr) * 1979-06-01 1981-01-07 The Wellcome Foundation Limited Dérivés de la triazine-1,2,4, procédé pour la préparation de tels composés et compositions pharmaceutiques les contenant
EP0247892A1 (fr) * 1986-05-30 1987-12-02 The Wellcome Foundation Limited Sels de triazine
EP0519602A1 (fr) * 1991-05-21 1992-12-23 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Utilisation d'un dérivé du dihydro-thiéno-pyridine pour l'inhibition de la libération cérébrale du glutamate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021121A1 (fr) * 1979-06-01 1981-01-07 The Wellcome Foundation Limited Dérivés de la triazine-1,2,4, procédé pour la préparation de tels composés et compositions pharmaceutiques les contenant
EP0247892A1 (fr) * 1986-05-30 1987-12-02 The Wellcome Foundation Limited Sels de triazine
EP0519602A1 (fr) * 1991-05-21 1992-12-23 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Utilisation d'un dérivé du dihydro-thiéno-pyridine pour l'inhibition de la libération cérébrale du glutamate

Also Published As

Publication number Publication date
ATE198831T1 (de) 2001-02-15
EP0689439B1 (fr) 2001-01-24
TW256773B (fr) 1995-09-11
GR3035528T3 (en) 2001-06-29
GB9305693D0 (en) 1993-05-05
DE69426622T2 (de) 2001-06-21
ZA941938B (en) 1995-09-18
AU6217694A (en) 1994-10-11
IL109034A (en) 1998-12-06
DK0689439T3 (da) 2001-04-17
JPH08507782A (ja) 1996-08-20
PT689439E (pt) 2001-05-31
DE69426622D1 (de) 2001-03-01
ES2153854T3 (es) 2001-03-16
EP0689439A1 (fr) 1996-01-03
IL109034A0 (en) 1994-06-24
WO1994021260A1 (fr) 1994-09-29
AP9400627A0 (en) 1994-04-30

Similar Documents

Publication Publication Date Title
AU622630B2 (en) D-cycloserine and its prodrugs as cognitive enhancers
EP0387867B1 (fr) Composition contenant du d-cyclosérine et de la d-alanine pour stimuler la mémoire et l'apprentissage ou pour le traitement d'un desordre cognitif ou psychotique
US5034400A (en) Method for preventing neurotoxic side effects of NMDA antagonists
US20060241144A1 (en) Method for treating apathy syndrome
JPWO2014133182A1 (ja) 眼炎症性疾患の予防及び／または治療剤
EP1020189B1 (fr) Nefiracetam pour la prevention ou le traitement de l'amnesie causee par propofol
US5866597A (en) Use of triazine compounds for the treatment of memory and learning disorders
AP478A (en) Use of triazine compounds for the treatment of impaired memory and learning disorders.
US6420404B2 (en) Use of amino-isoxazolidone compounds for improvement of implicit memory
US6399650B2 (en) Method for improving disturbancies of activities of daily living after stroke
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US6962921B2 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
US20020045565A1 (en) Method for treating or preventing emesis
BG63378B1 (bg) Използване на 1-ар(алк)ил-имидазолин-2-он за лечение на страхови и стресови състояния
GB2240476A (en) Use of 5HT-3 antagonist for preventing or reducing dependence
IE913211A1 (en) Use of n-(1-hexahydroazepinylalkyl) acetamides in the¹preparation of medicaments for the treatment of cholinergic¹transmission disorders